{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:41Z","timestamp":1790361701717,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00259-018-4200-3","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T04:58:17Z","timestamp":1541048297000},"page":"520-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?"],"prefix":"10.1007","volume":"46","author":[{"given":"Hajira","family":"Ilyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. George","family":"Mikhaeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel T.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareen","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5288","authenticated-orcid":false,"given":"Sally F.","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"issue":"8","key":"4200_CR1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00259-018-4005-4","volume":"45","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, et al. Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma? Eur J Nucl Med Mol Imaging. 2018;45(8):1463\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"4200_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","volume":"45","author":"H Ilyas","year":"2018","unstructured":"Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, M\u00f8ller H, Smith D, Barrington SF. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4200_CR3","doi-asserted-by":"crossref","unstructured":"Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Fingerle-Rowson G, Knapp A, Mattiello F, Nielsen T, Sellam G, Sahin D, Vitolo U, Trn\u011bn\u00fd M. Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA study. Blood. 2017.","DOI":"10.1002\/hon.2438_45"},{"key":"4200_CR4","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol. 2017;35:3529\u201337.","journal-title":"J Clin Oncol"},{"key":"4200_CR5","doi-asserted-by":"publisher","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS One. 2015;10:e0140830.","journal-title":"PLoS One"},{"key":"4200_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-4200-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-4200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T06:25:00Z","timestamp":1572589500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-4200-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4200"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-4200-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"16 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Patient data were extracted from case records and reviewed only by members of the responsible clinical team, in compliance with the UK Data Protection Act; consequently, specific Research Ethics Approval and individual patient consent were not required. Professor Barrington acknowledges support from the National Institute of Health Research (NIHR) [RP-2-16-07-001]. King\u2019s College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC, in association with the MRC and Department of Health (England).The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. She has received research funding from Hermes Medical Solutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}